Aksel Siva (Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey), a valued member of our European editorial board, talks to us about the topic of the interactive session he participated in focusing on treatment strategies in progressive multiple sclerosis.
1. What criteria should guide a clinician’s decision as to when to initiate and/or escalate disease-modifying treatment in progressive multiple sclerosis (MS)? (0:04)
2. What is the current status of research into predictors in progressive MS? (1:40)
Speaker disclosure: Aksel Siva has received honoraria for educational presentations and consultation fees from Novartis, Sanofi-Genzyme, F. Hoffmann-La Roche, Biogen Idec/Gen Pharma of Turkey, Merck Serono and Teva; received travel and registration coverage for attending several national or international congresses or symposia from Merck Serono, Biogen Idec/Gen Pharma of Turkey, Genzyme and , F. Hoffmann-La Roche.
Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2021: Flushing and Flushing-related Adverse Events – Results from the Phase 3 EVOLVE-MS-2 Study
It was a pleasure to meet with Dr Barry Singer (The MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, USA) to discuss the results of the phase 3 EVOLVE-MS-2 study, specifically looking at flushing and flushing related-adverse events with diroximel fumarate in patients with relapsing remitting multiple sclerosis. The abstract […]
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!